Orbimed Advisors Takes a Major Stake in Ambit Biosciences Corp (AMBI)

In the smart money’s world, Samuel Isaly’s Orbimed Advisors reported a purchase of some 2.1 million shares of Ambit Biosciences Corp (NASDAQ:AMBI) in a 13D filing with the SEC’s Edgar system. In total, at the current price of company’s shares, the value of the holding in Ambit Biosciences Corp (NASDAQ:AMBI) is now worth close to $14.42 million. This is a new position in Orbimed Advisors’s equity portfolio.

On the whole, 13Ds indicate the intentions of activist hedge fund managers. These members of the smart money are the proverbialcelebrities in the financial space, and seek to take a brush stroke to an already standing business model.

To put it simply, it’s very beneficial for everyday investors to internalize Samuel Isaly’s latest trade into Ambit Biosciences Corp (NASDAQ:AMBI).

Though the media, analysts and the blogosphere at large reports on a multitude of equity-based metrics, there is one that stands out: consensus sentiment of the world’s best money managers.

At Insider Monkey, our research has demonstrated that retail investors who copy specific hedge fund activity can outperform the market by as much as 18 percentage points per year. (See the details here).

Keying on Ambit Biosciences Corp (NASDAQ:AMBI), we should mention that the company has recently announced its Initial Publig Offering. According to a statement on the company’s website, the IPO involved about 8.2 million shares at a price of $8 apiece.

Moreover, we should mention some other stocks in Orbimed Advisors’s equity portfolio, in addition to Ambit Biosciences Corp (NASDAQ:AMBI).

As follows, they include Pfizer Inc. (NYSE:PFE), Biogen Idec Inc. (NASDAQ:BIIB), Merck & Co., Inc. (NYSE:MRK) and are discussed on the following page: